Safe Medicine Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Feb 18, 2020)
Safe Medicine Act
This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination.
The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.
What just happenedFeb 18, 2020
Referred to the House Committee on Energy and Commerce.
Who’s behind it
- Introduced in HouseFeb 18, 2020
- Feb 18, 2020IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Feb 18, 2020IntroReferralIntro-H
Introduced in House
- Feb 18, 2020IntroReferral1000
Introduced in House